Premium
Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin‐based chemotherapy
Author(s) -
Bellmunt J.,
Albanell J.,
Gallego O. S.,
Ribas A.,
Vicente P.,
Carulla J.,
De Torres J.,
Morote J.,
Lopez M.,
Solé L. A.
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19921001)70:7<1974::aid-cncr2820700727>3.0.co;2-d
Subject(s) - medicine , carboplatin , vinblastine , regimen , chemotherapy , methotrexate , bladder cancer , cisplatin , urology , chemotherapy regimen , cancer , surgery , creatinine , renal function , gastroenterology
Background . A Phase II trial with a new regimen of methotrexate, carboplatin, and vinblastine (M‐CAVI) was conducted for patients with bladder cancer who could not receive cisplatin‐based chemotherapy. Methods . Treatment consisted of methotrexate (30 mg/m 2 ) on days 1,15, and 22; carboplatin (300 mg/m 2 ) on day 2; and vinblastine (3 mg/m 2 ) on days 2, 15, and 22, scheduled at 28‐day intervals. The dosage of carboplatin was adjusted for creatinine clearance. Twenty‐five patients with metastatic (n = 9) or locally advanced or locoregional bladder cancer with a poor prognosis In (= 16) were treated with M‐CAW. Fifteen patients had abnormal serum creatinine levels, 4 had a low performance status, 3 had cardiac disease, and 3 were older than 70 years old. Results . Among 23 patients assessable for clinical response, the response rate was 48%. The median duration of response for metastatic disease was 7 months. Among nine patients assessable for pathologic response, there were two complete responses and three partial responses. The toxic effects have been moderate. Conclusions . M‐CAVI is an active and well‐tolerated regimen that can be used in patients with bladder cancer who are ineligible to receive cisplatin‐based chemotherapy. Cancer 1992; 70:1974–1979.